

A New Alternative for Your Patients




Fully Leverage the Immune System



Educate



Activate



Eliminate

By uniquely and specifically loading Dendritic Cells with both RNA and Proteins, we train the immune system to optimally attack cancer cells.

A First in Cancer Immunotherapy

Backed by decades of research and multiple FDA clinical trials, the Immunocine Dendritic Cell Treatment protocol is a less invasive, more precise way to treat over 30 different types of cancer.



Complete

Our Dendritic Cell Treatment initiates a complete Immune Response against your cancer cells. This top-down approach avoids the unspecific and ineffective targeting of other Immunotherapies.



Natural

Our Dendritic Cell Treatment does not introduce any foreign compounds or genetically modified cells into the body. By using your body's own cells, our treatment significantly reduces the risk of side effects.



Ongoing

Our Dendritic Cell Treatment fully activates the Immune System and continues after patients have received their last treatment. This Immunological Memory can make it harder for the cancer to return.



Scan to Watch Testimonials


www.immunocine.com

A Bold Treatment. A Hopeful Future.

In 2011, Dr. Matthew Halpert, PhD, joined a research team of Immunologists studying and developing a revolutionary approach to cancer treatment at the prestigious Texas Medical Center.



Leveraging the emerging science of immunotherapy, Dr. Halpert witnessed firsthand the powerful effects of this unique Dendritic Cell treatment both in the laboratory and in real-world case studies.

This work has resulted in multiple, active FDA Clinical Trials. While these trials represent significant potential for the future of cancer treatment, they don't help patients who do not qualify for the clinical trials.



The Only Dendritic Cell Treatment that Creates Significant Killer T Cell Activity

Unlike other Dendritic Cell treatments, ours is the first to “Double Load” the patient’s Dendritic Cells with their extracted cancer cells. This simulates a viral-like infection and initiates specific T Cells to seek and destroy the cancer cells throughout the patient’s body. Using this completely new approach to Dendritic Cell Treatments, the Immunocine Dendritic Cell Treatment (IDCT) protocol is able to not only generate a natural immune response, but one that is comprehensive enough to attack a patient’s cancer throughout their body.



Dendritic Cells are quantitatively and qualitatively optimized for Th1 immune propagation only when both MHC Class I and II pathways are loaded with homologous antigens (a.k.a. Identical source material). This is represented by this heatmap of the top 100 most differentially expressed genes (1750 analyzed) of purified human Dendritic Cells loaded various ways, in duplicate, and equally matured.



Decker WK, Xing D, Li S, *et al.* Th-1 Polarization is Regulated by Dendritic Cell Comparison of MHC Class I and Class II Antigens. *Blood*. 2009.
Halpert MM, Konduri V, Liang D, *et al.* MHC class I and II peptide homology regulates the cellular immune response. *FASEB*. 2020.

Decades of Research Hundreds of Validations → 1 Powerful Treatment

cGMP, ISO-Certified Cell Therapy Facility

Our cell therapy laboratory is one of the most advanced in Mexico. The lab equipment is equivalent to what is used at the Texas Medical Center for the clinical trials. And our state-of-the-art laboratory allows us to manufacture every personalized treatment to optimize patient safety and responses.



Backed by Peer-Reviewed Science

Since its discovery in 2006, the Immunocine Dendritic Cell Treatment (IDCT) Protocol has undergone continual research and clinical trials. It is a patented treatment and the first of its kind.

Effective Across a Variety of Cancers

We focus our entire program on this specific Dendritic Cell immunotherapy protocol. This is the same protocol that has been studied extensively and seen significant successes in multiple research labs, oncological facilities, and clinical trials.

Across a wide range of tough-to-treat cancers, our patients have seen incredible compassion and results with our treatment despite often being previously deemed refractory or incurable by their physicians.

Patient Testimonials



Babette L.

Stage 4 Ovarian Cancer

When Babette was diagnosed with metastatic growth near her heart, lungs and gall bladder, she faced an incredibly daunting battle for her life. After undergoing surgery to remove the tumors, the recommendation was to then do chemotherapy, which Babette had witnessed her best friend go through unsuccessfully just a year prior.

She then learned about the Immunocine Dendritic Cell Treatment. She contacted Matt Halpert, Ph.D to learn more and then knew this was her path forward. Now, nearly five years following her terminal diagnosis, Babette is cancer free and credits the IDCT with defeating her cancer.

“This is the absolute best treatment in my research and experience.”



Brock S.

Stage 4 Melanoma

Brock’s cancer was spreading aggressively throughout his body. The debilitating side effects of his treatment and his progressing disease left him frail and with limited mobility. Upon completion of his treatment at Immunocine, Brock witnessed an astonishing improvement in his health. He regained his mobility, and most notably, his more than 10 tumors started disappearing.

Al M.

Stage 4 Pancreatic

When Al was diagnosed, his oncologist told him that the survival rate for this cancer is measured in months. He tried multiple types of chemotherapy and immunotherapy along with surgery to no measurable improvements. He then found the IDCT and upon completion of his treatment, quickly noticed an improvement in his overall health and his most recent CT scans show no signs of cancer.



Kareema C.

Stage 4 Neuroendocrine Cancer

Relying on Lanreotide and diet changes, Kareema temporarily slowed her cancer’s progression. Unfortunately, her cancer progressed and her oncologist believed it was terminal. As a single mother, she refused to give up and found the IDCT. After treatment, she saw immediate success with her Chromagranin-A cancer markers falling from 7.6 nmol/L to 2.4nmol/L and a CT Scan detecting some of her tumors dissipating.



Justin H.

Stage 4 Kidney Cancer

While also navigating the uncertainties of the pandemic, Justin searched for answers, leading him to undergo surgery. Despite what appeared to be a successful surgery, he had a recurrence, leading him on a journey that would challenge the limits of traditional cancer treatment. After receiving the IDCT, his cancer markers dropped drastically. He's now thriving, having overcome a cancer with a five-year survival rate of less than 10%.

Martin L.

Stage 3B Prostate Cancer

After a suspicious and steady rise in his Prostate-Specific Antigen (PSA) levels, Martin underwent a biopsy. The results were stunning with a Gleason Score of 9. As he researched his options, he was determined to find a non-pharmacological, non-surgical and non-radiation approach, leading him to Immunocine. Now, more than a year following treatment, his cancer is stable and confined.



Kevin C.

Stage 2C Melanoma Cancer

From flying through the air on dirt bikes to operating heavy machinery, Kevin has always thrived in high-risk environments. But in 2022, he faced his greatest challenge yet: Stage 2C Melanoma Cancer. Despite undergoing multiple surgeries and treatments in Toronto, Kevin's condition stubbornly resurfaced, leaving him and his young family facing an uncertain future.

With everything on the line, Kevin and his wife discovered Immunocine and delved into the science behind the Immunocine Dendritic Cell Treatment (IDCT) before ultimately applying and being approved for treatment. In April 2023, Kevin embarked on the six-week treatment protocol at our center in Cancun. Just two months later, his oncologist in Toronto was astounded by the remarkable progress.

Today, Kevin is completely cancer-free, with multiple clean scans and biopsies to prove it. He credits the IDCT with not just saving his life, but also giving him a future to look forward to.

“As a patient, you’re looking for the science behind it and proof that it works. Immunocine has that.”



Treatment Timeline

Our treatment protocol is a unique and comprehensive immunotherapy spread over the course of six weeks. Patients can either stay in Cancun for the duration of their treatment or return home between stages.



Week 01 Treatment Prep & Creation

After arrival to Cancun, patients will be taken to our clinic to complete a pre-treatment health check and blood draw. Then, to increase white blood cell count, we will administer a subcutaneous injection of Neupogen (G-CSF), which is a natural cytokine found in the body. Following this, we will perform a biopsy to obtain a sample of the tumor. Over the following week, we will create a personalized treatment. During this time, patients are free to return home or stay in Cancun until the first treatment.

Week 02 First Dendritic Cell Treatment

Now that the personalized treatment has been created, patients are ready to receive their first treatment. We will administer it via Ultrasound-Guided Injection in a medically appropriate facility. The injection will target the closest lymph drainage point to the cancer to improve the immune response. This process takes no longer than 15 minutes and is completely outpatient. Following the injection, patients undergo two days of observation and check ups, which can be completed at their hotel. Once the observation period is complete, patients can stay in Cancun or return home.

Week 04 Second Dendritic Cell Treatment

After two weeks, the patient's Immune System will be ready for the second treatment. This follows the same process as the first and is supported by pre- and post- analysis and consultations to ensure safety and appropriate activity.

Week 06 Final Dendritic Cell Treatment

After two more weeks, the patient's Immune System will be ready for the final treatment. Following the same process as the prior two, we will perform the third injection. Upon completion of the post-analysis, they will be done with treatment and ready to return home.

Inclusion Criteria

To qualify for treatment, patients must meet the requirements outlined here.



Solid Tumors

While we are constantly expanding our capabilities, right now we only treat patients with solid tumors that can be biopsied. Blood malignancies, such as Leukemia, cannot be treated at this time.



Functioning Immune System

For any immunotherapy to be successful, a patient needs a stable, functioning immune system. Patients with immune deficiencies and other conditions may not qualify for treatment until normal activity is restored.



Ability to Travel

Some medical conditions and other factors may prevent patients from traveling and our treatment is only administered at our facilities in Cancun. If you are unable to travel, you will not be able to receive treatment.



6-Week Treatment

Our treatment protocol requires three separate treatments, each two weeks apart. Patients can either choose to stay in Cancun for six weeks or visit twice for two weeks at a time.



Stable Health

Impending organ failures would be a severe impediment to treatment response, thus proper functioning (e.g. liver, kidneys) is critical.



Non-Infectious Status

Due to safety protocols and equipment limitations, our lab is currently unable to process samples from individuals with active or recent infections of HIV, Hepatitis B, Hepatitis C, Syphilis, Chagas disease, Toxoplasmosis, or active Cytomegalovirus (CMV), or Epstein-Barr virus (EBV).



State-of-the-Art Facilities & Service

Until our treatment completes FDA Clinical Trials, it is only available at our facilities in Mexico. Fortunately, Cancun offers broader treatment options for patients who don't have time to wait.



The Most Advanced Hospitals in Mexico

There are three hospitals located within close proximity to our lab: Galenia, Amerimed and Joya. All three have state-of-the-art equipment, private rooms and are equipped to handle both emergency and routine care.



cGMP Practicing, ISO-Certified Lab

In compliance with cGMP and ISO 7 (Class 10,000 Grade C) standards, our cell therapy lab uses positive pressure clean rooms for the creation of each personalized treatment. All processes in our clean room involve the use of non-reusable sterile materials to avoid contamination.

Health License Registration

Immunocine operates under the following health licenses issued by the Mexican Government:
18-TR-23-005-0005, 18-TR-23-005-0003,
18-TR-23-005-0004.

Meet the Team

Our team of specialists have a vast array of experience in Cancer, Immunology and Cell Therapy. With a complete Medical Staff, Cell Therapy Team and Patient Support, we work seamlessly to provide the best patient experience possible.



Matthew Halpert, Ph.D

CEO

After earning his doctorate in Microbiology and Immunology, Dr. Halpert spent 10 years at Baylor College of Medicine in Houston as a Cancer Immunologist. While at BCM, he founded Diakonon Oncology, which is currently studying its revolutionary Dendritic Cell Treatment in multiple FDA clinical trials. In 2021, he left Baylor College of Medicine to found the Immunocine Cancer Center and continue his work at Diakonon Oncology.



Jay Hartenbach, MEM

COO

Jay is a passionate advocate for wellness and innovative healthcare, bringing a unique blend of scientific knowledge, entrepreneurial enthusiasm and business strategy to the space. As the COO, he leads the company in its mission to make its revolutionary approach to immunotherapy available to cancer patients.



Luis Ferbeyre, MD

Chief Medical Officer, Oncologist


Dr. Ferbeyre received his Medical Degree from the Medical University of Havana. After receiving his MD, Dr. Ferbeyre pursued Oncology with his thesis focused on Mixed Tumors within the Salivary Glands. Dr. Ferbeyre has published additional research on the genetic and molecular basis of cancer with 31 published peer-reviewed articles and has participated in multiple clinical trials.



Susana Hernandez, MSc

Director of Cell Therapy

Susana received her Undergraduate Degree in Pharmaceutical Science and her Master's Degree in Clinical Biomedicine from the University of the Americas Puebla (UDLAP). She received an additional Master's Degree in Bioethics from Anahuac University (Cancun). For the last 10 years, Susana has taught Molecular Biology, Genomics and Cell Physiology at Anahuac University (Cancun) and the University of Quintana Roo.



Gregorio Viramontes, MD

Interventional Radiologist

Dr. Viramontes received his Medical Degree from the National Autonomous University of Mexico (UNAM). With a focus on Radiology, he received his Board Certification from the Mexican Council of Radiology and Imaging. He has published 11 peer-reviewed papers regarding Radiology and Cancer. In addition, he is a professor at the Medical School of Anahuac (Cancun).



Francisco Zago, MD

General Physician

Dr. Zago is a dedicated physician with extensive experience in patient care, specializing in Primary Care. He received his medical education from Universidad Autónoma de Tlaxcala and Universidad Autónoma de Ciudad Juarez, and followed that by serving numerous in-need locations within Mexico. He holds multiple certifications in Regenerative Medicine and Cell Therapies, as well as being highly trained in various emergency situations.



Elideth Angulo, MD

General Physician

Dr. Angulo earned her degree at Universidad Autónoma de Ciudad Juarez in Chihuahua, Mexico. She has been practicing emergency, critical and primary care in the Cancun area for years. She's committed to improving the standard doctor-patient relationship by gaining a more thorough understanding of each and every one of her patients. She operates on the premise that a patient is not their cancer, but so much more.

A New Standard of Care for Cancer

At Immunocine, 85% of patients seen are deemed refractory or only palliatively treatable by conventional medicine. Since 2021, approximately 70% of patients see measurable, statistically significant benefit (e.g. Partial remission, stable, No evidence of disease (NED)). Approximately 25-33% of patients have been able to achieve NED status post Immunocine treatment, an exciting statistic especially considering that we continue to improve. And less than 10% of patients treated by Immunocine survived less than 6 months. Typical quality of life scores after Immunocine treatment are generally improved and may hover around an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 or a Karnofsky Performance Status (KPS) score >70.

A variety of cancers are amenable to this immunotherapy protocol, even if previously told “Immunotherapy will not work for them.” Objective and Targeted Immunological Responses are seen in approximately 90% of patients. Top side effects include fatigue, swollen lymph nodes, low grade fever, tenderness, and tumor associated pain and sensation. Examples of cancers that have responded to the level of NED – melanoma, bladder, renal, tonsillar, squamous cell carcinoma, pancreatic, colorectal, prostate, head and neck, ovarian, ER+ breast. Examples of cancer that have responded to the level of stable (>1year) – neuroendocrine, triple negative breast, ependymoma, chordoma, desmoplastic small-round-cell, peritoneal carcinomatosis. And the list continues to grow!



Approximate cost is \$100,000 USD, and includes all activities within the purview of this medical treatment. [See below.](#)

Travel and lodging are not included.



Medical Personnel

- Oncologist
- Radiologist
- General Internist
- Hematologist
- Angiologist
- Phlebotomists
- Nurses

Procedures

- US-Guided Injections of personalized vaccine
- Scans and Imaging
- Biopses
- Pathology
- Central Line
- Aphaeresis
- Blood Draws
- Microbubbling of Tumor*
- Overnight Hospital Stay

Scientific Personnel

- Scientists
- Cell Therapy Biologists
- Cellular Analytics Expert
- Cancer Immunotherapist

Vaccine Development

- Reagents
- Centrifuges
- Incubators
- Tissue Hoods
- Media and Cytokines
- QC Analysis
- mRNA Isolation
- mRNA Amplification
- Lysate Preparation
- Sterility
- Miscroscopy
- Flow Cytometry
- Storage of Boost
- Dendritic Cells
- Etc.

Coordination

- Patient Concierges
- Transportation
- Advisory Board

Medications

- Neupogen
- Pegylated IFN α
- Symptom Management

Data Analysis

- Radiology Reports
- Pathology Reports
- Dendritic Cell Qualification
- Immune System Analysis
- Blood Lab work
- Data Reports

Facilities

- cGMP ISO-7 Laboratory
- Procedure Rooms
- Private, Full-Service Hospital
- Imaging Centers
- Clinics

Support Team

- Ongoing and Remote Medical Support Team
- Ex: Integrative Oncologist, Functional Medicine Consultant, Nurse Navigator
- Continued Data Review
- Coordination With Home Medical*

**If desired and/or applicable*

Immunocine Cancer Center

A Guide to Our Treatment



Partner With Us to Treat Your Patients

We partner with physicians regularly to provide the Immunocine Dendritic Cell Treatment protocol to their late-stage cancer patients.



Collaboration

If your patient meets the minimum requirements and is interested in seeing how our treatment could work for their specific case, please submit their information on our submission form or call us directly at +1 (888) 575-2572.



Dedicated Support

Our team loves discussing our treatment with potential patients. We will schedule a call to learn about their diagnosis and answer initial questions. Prior to the call, we'll share additional info for them to review with their physician.



Medical Evaluation

After confirming their eligibility, we will perform a complimentary medical evaluation. This includes a questionnaire and review of their medical records. Once complete, they can be approved for treatment.



Scan to Learn More

www.immunocine.com

For more information regarding how we may collaborate to assist your patients, visit our website:
www.immunocine.com



Scan to
Learn More



Scan to Read
FAQs